Medical technology companies Rhisa and Gradient Health join forces to accelerate healthcare innovation by providing a new scale of diverse data to researchers from around the world.
giggsy25 Shutterstock
1310240776
Concept of data and partnership
Artificial intelligence (AI) has the potential to revolutionise medical technology, however its effectiveness can be hampered by using small, unrepresentative training datasets. This issue is also warranting significant attention from regulators, meaning developers now need to be sure their AI products have been trained on sufficiently diverse datasets before they can secure FDA or CE clearances.
Spanning two continents, this collaboration means patients across Europe and North America could benefit from new AI-powered medical technologies. Furthermore, researchers in these regions can now access compliant data quickly and securely.
Pierre Campredon, CEO of Rhisa, said: “Working with Gradient is an obvious direction for Rhisa as it multiplies the value creation for entire healthcare ecosystem. Furthermore, our mutual teams are fully supporting the mission driving Rhisa from day one: accelerating medical innovation with highly qualified data.”
Josh Miller, CEO of Gradient Health, added: “We’re thrilled to announce our collaboration with Rhisa. It’s great news for our clients and by extension the patients that will benefit from their technologies in the US and Europe.”
